PharmaShots | Incisive News in 3 Shots

Subscribe Now

merus

Merus Collaborates with Partner Therapeutics to Commercialize Zenocutuzumab for Treating NRG1 Fusion-Positive Cancer

Merus Collaborates with Partner Therapeutics to Commercialize Zenocutuzumab for Treating NRG1 Fusion-Positive Cancer

December 3, 2024

Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and Neck Squamous Cell Carcinoma (HNSCC)

Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and N...

October 1, 2024

Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

May 14, 2024

Merus Highlights the Preclinical Results from the Study of Zenocutuzumab for Cancer Treatment at the AACR 2024

Merus Highlights the Preclinical Results from the Study of Zenocutuzumab for Cancer Treatment at the AACR 2024

April 9, 2024

Merus and Gilead Enter into a Research Collaboration, Option & License Agreement to Discover of Antibody-Based Trispecific T-Cell Engagers

Merus and Gilead Enter into a Research Collaboration, Option & License Agreement to Discover of Antibody-Based Trispecific T-Cell...

March 7, 2024

Merus’ Zenocutuzumab Receives the US FDA’s Breakthrough Therapy Designation for NRG1 Fusion Non-Small Cell Lung Cancer

Merus’ Zenocutuzumab Receives the US FDA’s Breakthrough Therapy Designation for NRG1 Fusion Non-Small Cell Lung Cancer

July 6, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us